Therapeutic | Gimsilumab |
Target | CSF2 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS |
Light Chain | EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | MORPHODOMA Technology |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Ludwig Institute for Cancer Research, Morphotek |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Cancer, Rheumatoid arthritis |
Notes |